The expression of FBXO22 has been reported to be upregulated in hepatocellular carcinoma, pancreatic carcinoma, and melanoma and downregulated in ER+HER2- breast cancer and renal cell carcinoma [22, 23]. Here, ESR1 is linked to exocrine pancreatic carcinoma.